Economic savings versus health losses: The cost-effectiveness of generic antiretroviral therapy in the United States

BACKGROUND: US HIV treatment guidelines recommend branded once-daily, one-pill efavirenz/emtricitabine/tenofovir as preferred first-line antiretroviral treatment (ART). With the anticipated approval of generic efavirenz in 2012 in the US, the cost of a once-daily, three-pill alternative (generic efa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Walensky, Rochelle P., Sax, Paul E., Nakamura, Yoriko M., Weinstein, Milton C., Pei, Pamela P., Freedberg, Kenneth A., Paltiel, A. David, Schackman, Bruce R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3664029/
https://ncbi.nlm.nih.gov/pubmed/23318310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7326/0003-4819-158-2-201301150-00002
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados